Back to top
more

SiBone (SIBN)

(Delayed Data from NSDQ)

$16.55 USD

16.55
720,502

+1.65 (11.07%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.

Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test

Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.

Syneos Health (SYNH) to Go Private, Reports Q2 Performance

Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.

Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?

Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.

Charles River (CRL) to Report Q2 Earnings: What's in Store?

Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.

Can Conifer Weakness Affect Tenet Healthcare's (THC) Q2 Earnings?

Tenet Healthcare's (THC) second-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.

CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 1.75% and 10.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Higher Costs Affect HCA Healthcare's (HCA) Q2 Earnings?

HCA Healthcare's (HCA) second-quarter results are likely to reflect increased patient volumes, occupancy rate and cost of supplies.

InMode (INMD) to Post Q2 Earnings: What's in the Cards?

InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.

What's in Store for Canopy Growth (CGC) in Q1 Earnings?

Strong demand for legal cannabis products in the Canadian recreational cannabis market and the launch of new products are expected to have driven Canopy Growth's (CGC) Q1 performance.

Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?

Zimmer Biomet (ZBH) is expected to have witnessed procedure recovery in its legacy business in the second quarter.

Breast Health Arm to Boost Hologic (HOLX) in Q3 Earnings

Hologic's (HOLX) Breast Health is likely to have driven Q3 performance, owing to strong performance from improved semiconductor chip availability and strong backlog.

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

The growing adoption of Panther instruments and an expanded Panther installed base as well as strength in Breast Health is expected to have driven Hologic's (HOLX) Q3 revenues.

Will Boston Scientific (BSX) Beat Q2 Earnings Estimates?

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN and other interventional cardiology therapies.

LabCorp (LH) to Report Q2 Earnings: What's in the Cards?

Sales rebound in the base business for Diagnostics business and strong drug development orders are expected to have driven LabCorp's (LH) second-quarter performance.

Quest Diagnostics (DGX) to Post Q2 Earnings: What's in Store?

Quest Diagnostics (DGX) second-quarter results are likely to have reflected the solid base business performance and benefits from acquisitions.

Alcon (ALC) Gains From Robust Contact Lense Sales, Launches

In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.

What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in TAVR procedures globally.

Align Technology's (ALGN) New Pacts, Innovation Aid Growth

Align Technology's (ALGN) Invisalign comprehensive witnesses strong initial adoption in the market.

Labcorp (LH) Completes Strategic Deal With Jefferson Health

Labcorp's (LH) agreement with Jefferson to build academic collaborations around teaching and developing innovative tests.

Will Carelon Growth Aid Elevance Health's (ELV) Q2 Earnings?

Elevance Health's (ELV) second-quarter results are likely to reflect rising memberships in Medicare Advantage, Medicaid, Vision and Dental Administration businesses.

Quest Diagnostics (DGX) Brings New Test for Prostate Cancer

Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.

Labcorp (LH) Inks Asset Acquisition Deal With Legacy Health

Labcorp's (LH) new agreement with Legacy Health will broaden access to its Diagnostics capabilities and improve services.

Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System

Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.

Penumbra (PEN) Gains on New Launches Amid Currency Headwind

Penumbra's (PEN) ability to improve net gross margins and EPS amid ongoing inflationary pressure and supply-chain headwinds buoy optimism.